Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment

Mary A. De Groote, Payam Nahid, Leah Jarlsberg, John L. Johnson, Marc H Weiner, Grace Muzanyi, Nebojsa Janjic, David G. Sterling, Urs A. Ochsner

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

In an unbiased approach to biomarker discovery, we applied a highly multiplexed proteomic technology (SOMAscan, SomaLogic, Inc, Boulder, CO) to understand changes in proteins from paired serum samples at enrollment and after 8 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in the Center for Disease Control and Prevention's Tuberculosis Trials Consortium (TBTC) Study 29. This work represents the first large-scale proteomic analysis employing modified DNA aptamers in a study of active tuberculosis (TB). We identified multiple proteins that exhibit significant expression differences during the intensive phase of TB therapy. There was enrichment for proteins in conserved networks of biological processes and function including antimicrobial defense, tissue healing and remodeling, acute phase response, pattern recognition, protease/anti-proteases, complement and coagulation cascade, apoptosis, immunity and inflammation pathways. Members of cytokine pathways such as interferon-gamma, while present, were not as highly represented as might have been predicted. The top proteins that changed between baseline and 8 weeks of therapy were TSP4, TIMP-2, SEPR, MRC-2, Antithrombin III, SAA, CRP, NPS-PLA2, LEAP-1, and LBP. The novel proteins elucidated in this work may provide new insights for understanding TB disease, its treatment and subsequent healing processes that occur in response to effective therapy.

Original languageEnglish (US)
Article numbere61002
JournalPLoS One
Volume8
Issue number4
DOIs
StatePublished - Apr 18 2013

Fingerprint

Biomarkers
Pulmonary Tuberculosis
tuberculosis
biomarkers
Tuberculosis
lungs
Serum
Proteins
Proteomics
proteins
Peptide Hydrolases
proteomics
therapeutics
Nucleotide Aptamers
Disease control
Biological Phenomena
proteinases
Therapeutics
Tissue Inhibitor of Metalloproteinase-2
Acute-Phase Reaction

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

De Groote, M. A., Nahid, P., Jarlsberg, L., Johnson, J. L., Weiner, M. H., Muzanyi, G., ... Ochsner, U. A. (2013). Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment. PLoS One, 8(4), [e61002]. https://doi.org/10.1371/journal.pone.0061002

Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment. / De Groote, Mary A.; Nahid, Payam; Jarlsberg, Leah; Johnson, John L.; Weiner, Marc H; Muzanyi, Grace; Janjic, Nebojsa; Sterling, David G.; Ochsner, Urs A.

In: PLoS One, Vol. 8, No. 4, e61002, 18.04.2013.

Research output: Contribution to journalArticle

De Groote, MA, Nahid, P, Jarlsberg, L, Johnson, JL, Weiner, MH, Muzanyi, G, Janjic, N, Sterling, DG & Ochsner, UA 2013, 'Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment', PLoS One, vol. 8, no. 4, e61002. https://doi.org/10.1371/journal.pone.0061002
De Groote, Mary A. ; Nahid, Payam ; Jarlsberg, Leah ; Johnson, John L. ; Weiner, Marc H ; Muzanyi, Grace ; Janjic, Nebojsa ; Sterling, David G. ; Ochsner, Urs A. / Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment. In: PLoS One. 2013 ; Vol. 8, No. 4.
@article{c00752dd86d746e59bd4640b92f04c11,
title = "Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment",
abstract = "In an unbiased approach to biomarker discovery, we applied a highly multiplexed proteomic technology (SOMAscan, SomaLogic, Inc, Boulder, CO) to understand changes in proteins from paired serum samples at enrollment and after 8 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in the Center for Disease Control and Prevention's Tuberculosis Trials Consortium (TBTC) Study 29. This work represents the first large-scale proteomic analysis employing modified DNA aptamers in a study of active tuberculosis (TB). We identified multiple proteins that exhibit significant expression differences during the intensive phase of TB therapy. There was enrichment for proteins in conserved networks of biological processes and function including antimicrobial defense, tissue healing and remodeling, acute phase response, pattern recognition, protease/anti-proteases, complement and coagulation cascade, apoptosis, immunity and inflammation pathways. Members of cytokine pathways such as interferon-gamma, while present, were not as highly represented as might have been predicted. The top proteins that changed between baseline and 8 weeks of therapy were TSP4, TIMP-2, SEPR, MRC-2, Antithrombin III, SAA, CRP, NPS-PLA2, LEAP-1, and LBP. The novel proteins elucidated in this work may provide new insights for understanding TB disease, its treatment and subsequent healing processes that occur in response to effective therapy.",
author = "{De Groote}, {Mary A.} and Payam Nahid and Leah Jarlsberg and Johnson, {John L.} and Weiner, {Marc H} and Grace Muzanyi and Nebojsa Janjic and Sterling, {David G.} and Ochsner, {Urs A.}",
year = "2013",
month = "4",
day = "18",
doi = "10.1371/journal.pone.0061002",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment

AU - De Groote, Mary A.

AU - Nahid, Payam

AU - Jarlsberg, Leah

AU - Johnson, John L.

AU - Weiner, Marc H

AU - Muzanyi, Grace

AU - Janjic, Nebojsa

AU - Sterling, David G.

AU - Ochsner, Urs A.

PY - 2013/4/18

Y1 - 2013/4/18

N2 - In an unbiased approach to biomarker discovery, we applied a highly multiplexed proteomic technology (SOMAscan, SomaLogic, Inc, Boulder, CO) to understand changes in proteins from paired serum samples at enrollment and after 8 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in the Center for Disease Control and Prevention's Tuberculosis Trials Consortium (TBTC) Study 29. This work represents the first large-scale proteomic analysis employing modified DNA aptamers in a study of active tuberculosis (TB). We identified multiple proteins that exhibit significant expression differences during the intensive phase of TB therapy. There was enrichment for proteins in conserved networks of biological processes and function including antimicrobial defense, tissue healing and remodeling, acute phase response, pattern recognition, protease/anti-proteases, complement and coagulation cascade, apoptosis, immunity and inflammation pathways. Members of cytokine pathways such as interferon-gamma, while present, were not as highly represented as might have been predicted. The top proteins that changed between baseline and 8 weeks of therapy were TSP4, TIMP-2, SEPR, MRC-2, Antithrombin III, SAA, CRP, NPS-PLA2, LEAP-1, and LBP. The novel proteins elucidated in this work may provide new insights for understanding TB disease, its treatment and subsequent healing processes that occur in response to effective therapy.

AB - In an unbiased approach to biomarker discovery, we applied a highly multiplexed proteomic technology (SOMAscan, SomaLogic, Inc, Boulder, CO) to understand changes in proteins from paired serum samples at enrollment and after 8 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in the Center for Disease Control and Prevention's Tuberculosis Trials Consortium (TBTC) Study 29. This work represents the first large-scale proteomic analysis employing modified DNA aptamers in a study of active tuberculosis (TB). We identified multiple proteins that exhibit significant expression differences during the intensive phase of TB therapy. There was enrichment for proteins in conserved networks of biological processes and function including antimicrobial defense, tissue healing and remodeling, acute phase response, pattern recognition, protease/anti-proteases, complement and coagulation cascade, apoptosis, immunity and inflammation pathways. Members of cytokine pathways such as interferon-gamma, while present, were not as highly represented as might have been predicted. The top proteins that changed between baseline and 8 weeks of therapy were TSP4, TIMP-2, SEPR, MRC-2, Antithrombin III, SAA, CRP, NPS-PLA2, LEAP-1, and LBP. The novel proteins elucidated in this work may provide new insights for understanding TB disease, its treatment and subsequent healing processes that occur in response to effective therapy.

UR - http://www.scopus.com/inward/record.url?scp=84876301737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876301737&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0061002

DO - 10.1371/journal.pone.0061002

M3 - Article

C2 - 23637781

AN - SCOPUS:84876301737

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e61002

ER -